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Insulin resistance induced by a high fructose diet has been associated to hypertension and 
renal damage. The aim of this work was to assess alterations in the urinary L-
dopa/dopamine ratio over three time periods in rats with insulin resistance induced by 
fructose overload and its correlation with blood pressure levels and the presence of 
microalbuminuria and reduced nephrin expression as markers of renal structural damage. 
Male Sprague-Dawley rats were randomly divided in six groups: control (C) (C4, C8 and 
C12) with tap water to drink; and fructose-overloaded (FO) rats, (FO4, FO8 and FO12), 
with a fructose solution (10% w/v) to drink; for 4, 8 and 12 weeks. A significant increase of 
the urinary L-dopa/dopamine ratio was found in FO rats since week 4, which positively 
correlated to the development of hypertension and preceded in time the onset of 
microalbuminuria and reduced nephrin expression observed on week 12 of treatment. 
The alteration of this ratio was associated to an impairment of the renal dopaminergic 
system, evidenced by a reduction in renal dopamine transporters and dopamine D1 
receptor expression, leading to an over-expression and over-activation of the enzyme Na+, 
K+- ATPase with sodium retention. In conclusion, urinary L-dopa/dopamine ratio alteration 
in rats with fructose overload positively correlated to the development of hypertension 
and preceded in time the onset of renal structural damage. This is the first study to 
propose the use of the urinary L-dopa/dopamine index as marker of renal dysfunction that 
temporarily precedes kidney structural damage induced by fructose overload. 
 



















Fructose is a simple and highly lipogenic sugar present in added dietary sugars, 
honey and fruit [1]. Fructose consumption has been associated to many of the 
components of metabolic syndrome such as insulin resistance, dyslipidemia, and 
hypertension [2]. In fact, a well-known experimental model of metabolic syndrome is 
based on a diet characterized by high fructose consumption [2-4].  Many mechanisms link 
insulin resistance with hypertension, including an increase in sodium reabsorption and 
stimulation of sympathetic nervous and renin-angiotensin systems [5-7]. On the other 
hand, several studies have suggested a close relationship between metabolic syndrome 
and renal damage [8,9]. In this way, insulin resistance induced by long term exposure to a 
high fructose diet is associated to renal structural damage, evidenced by kidney 
inflammation, proteinuria, glomerular hypertrophy, sclerosis and tubulointerstitial injury 
[10,11]. 
Renal dopamine, synthesized in tubular cells, acts as a local, non-neural and 
natriuretic system that regulates renal function and blood pressure levels through 
inhibition of sodium transporters at tubular level, being the most important the enzyme 
Na+, K+- ATPase [12,13]. Several studies have established a relationship between insulin 
resistance and the impairment of renal dopaminergic system (RDS) in the pathogenesis of 
hypertension. In this way, alterations in dopamine receptor D1 (D1R) were associated to 
hyperinsulinemia-induced hypertension in different animal models of obesity and 
















production in proximal tubular cells in rats with insulin resistance induced by fructose 
overload [16]. 
The conversion of L-Dopa to dopamine in the kidneys accounts for all the free 
dopamine found in urine [17]. Therefore, the ratio between urinary L-dopa and dopamine 
could reflect RDS functionality. Considering these facts, it can be proposed that the 
urinary L-dopa/dopamine index could be altered in pathological conditions that lead to 
renal dysfunction such as insulin resistance. To date, there is no evidence regarding the 
use of urinary L-dopa/dopamine index as an early biochemical marker of renal dysfunction 
that could precede and anticipate renal established structural damage associated to 
insulin resistance in this model of metabolic syndrome. 
The aim of the present study was to evaluate the alterations in the urinary L-
dopa/dopamine index over three time periods in rats with metabolic syndrome induced 
by fructose overload and its correlation with blood pressure levels and the presence of 
microalbuminuria and reduced expression of nephrin as indicators of renal structural 
damage. 
 
2. Materials and Methods 
2.1 Animal protocol and diet 
Male Sprague-Dawley rats weighing 180-200 g at the beginning of the study were 
used. The experiments were approved in advance by the local ethics committee on animal 
research (protocol #2100-15; 0035638/15) according to “International Ethical Guiding 
















International Organizations of Medical Sciences). Animals were housed in cages with a 12-
hour light/dark cycle under conditions of controlled temperature (22±2ºC) and humidity. 
Until the day of the experiment all animals were given free access to liquid and fed with 
standard chow with the following composition (w/w): 20% proteins, 3% fat, 2% fiber, 6% 
minerals and 69% starch and vitamin supplements (Commercial Rodents Purina Chow; 
Cooperación SRL, Buenos Aires, Argentina). 48 rats were randomly divided in six groups 
and studied at 4, 8 and 12 weeks of treatment: Three control (C) groups (C4, C8 and C12), 
with tap water to drink, and three experimental fructose-overloaded (FO) groups, (FO4, 
FO8 and FO12), with fructose (Parafarm, Buenos Aires, Argentina) solution (10% w/v) to 
drink (n=8 for each group).  The rats were weighed before dietary manipulation and at the 
end of each experimental period. 
2.2 Systolic blood pressure measurement  
The rats were trained to the procedure of blood pressure measurement at 10.00 
AM, twice a week, for 2 weeks, after randomization (baseline blood pressure), and prior to 
be sacrificed. Indirect systolic blood pressure (SBP) was measured by means of a 
photoelectric tail-cuff connected to an amplifier (II TC model 47; Innovators in 
Instrumentation, Landing, NJ, USA) in series with an oscilloscope (type 532, Tektronic Inc., 
Portland, OR, USA).  
2.3 Measurement of food, fluid and caloric intake 
Three days before the end of each period time, the rats were placed in metabolic 
cages for 48 hours in order to allow adaptation to the new environment. Food 
















rats, respectively. Caloric intake for control rats was calculated using the formula for 
standard rat chow [food intake (g) x 3.3 kcal/g], while caloric intake for FO rats was 
calculated using the formula [food intake (g) x 3.3 kcal/g] + fructose intake (mL) x 0.4 
kcal/mL]. 
2.4 Blood samples recollection and biochemical measurements 
After 4, 8 or 12 weeks, all groups of experimental and control animals were fasted 
for 5 hours. Under anesthesia with ketamine (80 mg/kg, PRO-SER SA) and xylazine (12 
mg/kg, PRO-SER SA), blood samples were collected to measure plasma triglycerides, 
cholesterol, glucose and insulin levels. Plasma triglyceride and cholesterol levels were 
measured by means of commercial kits (TG Color GPO/PAP AA, Colestat Wiener Labs, 
Rosario, Santa Fé, Argentina) using a spectrophotometric method; plasma glucose was 
determined by a blood glucose meter (Accu-Chek, Roche Diagnostics GmbH, Mannheim, 
Germany) and insulin by ELISA (Millipore Corporation, Billerica, MA, USA). Homeostasis 
model of assessment – insulin resistance index (HOMA-IR) was calculated by using the 
following equation: HOMA = fasting glucose (mmol/L) x fasting insulin (mIU/L)/22.5, being 
2.5 points or higher, the cut-off point to define insulin resistance [18]. 
2.5 Urine samples recollection and urinary measurements 
Using the metabolic cages, 24 hour urinary samples from control and FO rats were 
collected at the end of each experimental period to determine diuresis and urinary 
excretion of L-dopa, dopamine, sodium and creatinine. To determine urinary L-dopa and 
dopamine concentration by HPLC, a fraction of urine was collected at the end of the 
















2.5.1 Renal function parameters calculation 
To evaluate renal functionality, the following parameters were determined: urine 
and plasma sodium and creatinine (by standard methods using an autoanalyzer), 
glomerular filtration rate (GFR) estimated by creatinine clearance (CrCl), fractional and 
urinary sodium excretion (FENa and UNa.UV, respectively) and daily diuresis. FENa, 
UNa.UV and CrCl were calculated according to standard formula. Daily diuresis is 
expressed as mL/day/kg, CrCl as mL/min/kg, UNa.UV as mEq/day/kg and FENa as the 
percentage (%) of filtered sodium.  
2.5.2 Urinary L-dopa and dopamine assay 
A 50-μl aliquots of urine were partially purified by batch alumina extraction, 
separated by reverse-phase high-pressure liquid chromatography (RP-HPLC) using a 
4.6×250 mm Zorbax RxC18 column (DuPont Company, Delaware, USA) and quantified 
amperometrically by the current produced upon exposure of the column effluent to 
oxidizing and then reducing potentials in series using a triple-electrode system (ESA, 
Bedford, Mass., USA). Recovery through the alumina extraction step averaged 80–90%. L-
dopa and dopamine concentrations in each sample were corrected for recovery of an 
internal standard. Levels of L-dopa and dopamine were further corrected for differences 
in recovery of the internal standard in a mixture of external standards. The limit of 
detection was about 20 pg/volume assayed. 
















After urine and blood samples collection, the animals were sacrificed and both 
kidneys were dissected and then processed to perform biochemical and molecular 
analyses. 
2.6.1 Western blot analyses  
Semiquantitative Western blot analyses were carried out in renal cortex from all 
animals. Expression of L-dopa transporters (LAT-1, LAT-2), dopamine transporters (OCT-2, 
OCT-N1/2/3, OCT-N1), dopamine receptor (D1R) and nephrin was studied. The right 
kidney from all animals was removed and the renal cortex was immediately dissected and 
separated under refrigeration. Tissue samples were then homogenized on ice with a 
Tissue Tearor (Biospec Products Inc, Bartesville, Oklahoma, USA), 1:3 weight/volume, in a 
buffer mixture: 50 mmol/L Tris, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1% Triton-X-100, 1 
mmol/L PMSF, 1 μmol/L pepstatin, and 2 μmol/L leupeptin, 1x protease inhibitor cocktail 
(Roche Diagnostics, Buenos Aires, Argentina). Then, samples were centrifuged at 3400 g 
and 4°C during 15 minutes. Protein concentration in the Triton-soluble supernatant was 
determined by Lowry technique [19]. Samples of renal cortex, containing similar amounts 
of protein (100 μg protein/lane) were separated by electrophoresis in 10% SDS-
polyacrylamide gels (Bio-Rad Labs Inc, Hercules, California, USA) and then transferred to a 
PVDF membrane (Bio-Rad Labs Inc) and incubated with goat polyclonal anti-LAT-1 (Santa 
Cruz Biotechnology, Inc., Dallas, Texas, USA, 1:800 dilution), goat polyclonal anti-LAT-2 
(Santa Cruz Biotechnology, Inc. 1:2000 dilution), goat polyclonal anti- OCT-2 (Santa Cruz 
Biotechnology, Inc. 1:800 dilution), rabbit polyclonal anti- OCT-N1/2/3  (Santa Cruz 
















Biotechnology, Inc. 1:800 dilution), goat polyclonal anti-D1R (Santa Cruz Biotechnology, 
Inc. 1:800 dilution) or goat polyclonal anti- nephrin (Santa Cruz Biotechnology, Inc. 1:400 
dilution). A secondary immunoreaction was performed with a biotinilated donkey antigoat 
IgG or antirabbit IgG respectively (Santa Cruz Biotechnology, Inc. 1:1500 dilution), 
followed by a third step using streptavidin conjugated with horseradish peroxidase (GE 
Healthcare Life Sciences; Buenos Aires, Argentina, dilution of 1:2000). The samples were 
revealed by chemiluminescence using ECL reagent (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA) for 1–5 min. The density of the respective bands was quantified by 
densitometric scanning using a Hewlett-Packard scanner and Image J analyzer software 
(RSB). To avoid inaccuracies in protein loading, GAPDH or beta-tubulin were measured as 
internal standard (Santa Cruz, anti-GAPDH rabbit polyclonal first antibody, dilution of 
1:2000; Abcam, anti-beta-tubulin rabbit polyclonal first antibody, dilution of 1:2000, 
second biotinilated anti-rabbit antibody, 1:2000 dilution; third streptavidin conjugated 
with horseradish peroxidase, 1:2000 dilution) for each blot. Protein levels were calculated 
and expressed as the ratio between the optical densities of the bands corresponding to 
LAT-1, LAT-2, OCT-2, OCT-N1/2/3, OCT-N1, D1R and nephrin and the one corresponding to 
the respective internal standard. 
2.6.2 Immunofluorescence  
Immunofluorescence detection of Na+, K+-ATPase was performed on renal cortex 
from all animals. A sagittal cut of the left kidney from all animals was performed. Then, 
the tissues were fixed in a solution of 10% paraformaldehyde (pH 7.20) and then 
















tissue sections were cut using a cryostat. Three micron sections were made and mounted 
on slides for immunofluorescence. After washing with cold Ringer buffer, the nonspecific 
binding sites were blocked by incubating at 22°C with Ringer's buffer containing 0.5% 
gelatin for 30 minutes. They were incubated at 4°C overnight with specific purified rabbit 
anti total Na+, K+-ATPase antibody (Abcam, Cambridge, UK, 1:250 dilution). Then, they 
were washed with phosphate saline buffer (PBS) and incubated for 45 minutes at dark 
with corresponding marked secondary antibody (donkey anti-rabbit IgG FITC, Santa Cruz 
Biotechnology, Inc., 1:500 dilution in PBS). 
2.6.3 Specific Activity of Na+, K+-ATPase 
Sample tissues from renal cortex weighing 50 mg were homogenized (1:10 
weight/volume) in 25mM imidazole/1mM EDTA/0.25M sucrose solution and centrifuged 
at 4700 g at 4°C for 15 minutes. Na+, K+-ATPase activity was assayed in the supernatant 
using Fiske-Subbarrow method [20]. ATPase activity was measured by colorimetric 
determination of released orthophosphate and ouabain was used to inhibit specifically 
Na+, K+-ATPase activity [21]. Proteins were determined by the method of Lowry et al [19]. 
Results are expressed as percentage of Na+, K+-ATPase activity, considering control values 
as 100%. 
2.7 Statistical analysis 
All results are expressed as means ± SEM. Data was processed using Graph Pad 
InStat Software (San Diego, CA, USA). The Gaussian distribution was evaluated by the 
Kolmogorov Smirnov method and to compare between groups, ANOVA followed by 
















using Kruskal-Wallis test (Nonparametric ANOVA) and multiple comparison test of Dunn, 




3.1 Physiological and metabolic parameters 
As shown in table 1, FO rats had significant higher fluid intake and lower food 
intake compared to control rats from week 4 of treatment. Caloric intake did not differ 
between control and FO rats for each experimental period. Body weight did not differ 
between control and FO animals in any experimental period. SBP significantly increased 
from week 4 of treatment in FO rats compared to control groups, reaching higher levels at 
weeks 8 and 12. Plasma triglyceride levels significantly increased since week 8 of fructose 
overload, without significant changes in total cholesterol values in any experimental 
period. Fructose overload significantly increased plasma insulin levels from week 4 of 
treatment compared to control rats, while blood glucose levels were higher, but not 
significantly different, in FO rats at 4 , 8 and 12 weeks. HOMA-IR levels significantly 
increased in FO respect to control rats and were higher than 2.5 since week 4.  
3.2 Renal function parameters 
Table 2 shows that daily diuresis significantly increased in FO animals from week 4, 
compared to control groups. Sodium urinary excretion and fractional excretion of sodium 
were significantly reduced in FO rats throughout all treatment. Furthermore, creatinine 
















 3.3 Renal dopaminergic system 
3.3.1 L-dopa and dopamine excretion 
Urinary L-Dopa excretion significantly increased along all the treatment with 
fructose while urinary dopamine excretion simultaneously decreased, compared to 
control levels (figure 1). The urinary L-dopa/dopamine ratio significantly increased in FO 
rats from week 4, as regard to their respective controls (figure 2).  Figure 3 shows a 
positive and significant correlation between the elevation of SBP and urinary L-
dopa/dopamine ratio levels along the 12 weeks of fructose treatment. 
3.3.2 Renal expression of L-dopa and dopamine transporters and D1 receptor 
LAT-1 expression did not change in FO animals in any of the experimental periods, 
compared to control rats (figure 4a). Conversely, LAT-2 expression significantly increased 
since week 4 of treatment with fructose, suggesting a possible increase in L-dopa uptake 
process by tubular cells compared to controls (figure 4b). OCT-2 expression significantly 
diminished since week 8 in FO rats respect to controls (figure 5a). These changes were  
accompanied by a significant reduction of OCT-N1/2/3 and OCT-N1 expression since the 
same week (figures 5b and 5c). On the other hand, D1R  expression was reduced in FO rats 
since week of 4 compared to control rats (figure 5d). 
3.3.3 Na+, K+-ATPase expression and specific activity  
Specific activity levels of Na+, K+-ATPase in renal cortex were significantly increased 
from week 4 of treatment with fructose respect to control groups (figure 6). Na+, K+-
ATPase expression, determined by immunofluorescence, increased in renal cortex in FO 
















3.4 Biomarkers of renal damage 
Microalbuminuria was defined as a urinary albumin/creatinine ratio between 30-
300 mg/g. The presence of microalbuminuria was detected in week 12 of treatment with 
fructose (figure 8). A significant reduction of nephrin expression was observed at the same 
experimental period in FO rats compared to controls (figure 9). 
 
4. Discussion 
 Experimental models of metabolic syndrome, such as the model of FO in the 
diet, are characterized by hemodynamic and metabolic changes including 
hyperinsulinemia and insulin resistance, dyslipidemia and hypertension, and are useful to 
investigate the pathophysiological processes that lead to kidney damage and their clinical 
implications [5,22]. In our study, plasma insulin levels were significantly increased in FO 
rats compared to controls since week 4. Plasma glucose levels were also higher in FO 
respect to control rats, although the difference was not significant. Rats with FO showed 
significantly higher levels of HOMA index compared to control rats since week 4 of 
treatment, reaching higher values at weeks 8 and 12, indicating the development of 
insulin resistance [18]. Regarding lipid metabolism, FO rats exhibited increased plasma 
triglycerides since week 8 of treatment without changes in total cholesterol in any 
experimental period compared to control rats. It is well established that fructose leads to 
an increase in plasma triglycerides, which in turn contributes to the development of 
















Body weight values did not differ between control and FO animals in any 
experimental period. The absence of body weight gain in rats with a high fructose diet has 
been reported in several studies [22,24]. At the same time, caloric intake between FO and 
control rats was not different either. This could be explained by the fact that in FO 
animals, the increase in caloric intake given by fructose intake was compensated by a 
reduction in food intake, compared to control rats.  
Concerning renal function, the 24 hour diuresis significantly increased in FO rats 
respect to controls. This increment is explained as a consequence of increased fluid intake 
in FO compared to control rats, which has been well documented [3]. One explanation 
could be the sweet taste of the solution that would enhance the palatability thereby 
increasing fluid intake [3]. On the other hand, urinary sodium excretion and urinary 
fractional excretion were significantly reduced in rats with FO since week 4 of treatment, 
indicating the existence of sodium retention. Many authors have suggested that increased 
renal sodium reabsorption induced by insulin is enhanced in insulin resistance states and 
possibly contributes in part to the development of hypertension [25]. 
In addition, RDS constitutes a local natriuretic system that regulates sodium 
excretion and blood pressure levels and several studies have established a relationship 
between insulin resistance and the RDS in the pathogenesis of hypertension [13,16]. Our 
results show an increase in the urinary L-dopa/dopamine ratio in FO rats from week 4 of 
treatment, indicating the existence of an impairment in renal dopamine synthesis in this 
model. The increase in L-dopa/dopamine ratio was due to a significant decrease in urinary 
















dopa uptake through the apical membrane of proximal tubular cells represents the rate-
limiting step in dopamine synthesis, and it is mediated by at least, two major Na+-
independent amino-acid transporters, named LAT and bo.+ systems [26]. Alterations in L-
dopa uptake in states of insulin resistance have been described [27]. Although, we found 
no significant difference in LAT-1 expression in FO rats compared to controls in any 
experimental period, while LAT-2 expression was significantly increased in FO versus 
control rats since week 4. This increase would imply an increase in L-dopa uptake and a 
decrease in urinary L-dopa excretion. Nonetheless, the results obtained in our study are in 
accordance with previous findings that indicate a reduced L-dopa uptake in insulin 
resistance states [27,28]. One possibility that would explain high values of urinary L-dopa 
with an increased LAT-2 expression is that these transporters could show a defect in their 
activity, being unable to enter L-dopa into the tubular cells. Another possibility is that LAT-
2 increased expression could be located on intracellular stores and not necessarily 
inserted in the plasma membrane. Further experiments would be needed to confirm or 
discard any of these hypotheses. 
In order to achieve its actions, dopamine must leave the proximal tubular cells 
through the apical border to reach the tubular lumen, where it can bind and activate 
specific dopamine receptors located outside the apical border of tubular cells. Dopamine 
can be uptaken from plasma into proximal tubule by members of the SLC22A family 
(solute carrier superfamily) called organic cation transporters (OCT-1, OCT-2 and OCT-3) 
located at the basolateral membrane. Dopamine leaves the tubular cells by other 
















at the apical membrane [29]. The lower urinary excretion of dopamine observed in our 
experimental model could be a consequence of an impairment in dopamine 
transportation by OCTs and OCTNs. In this sense, reduced expression of OCT-N1 from 
week 8 in FO rats compared to controls was consistent with reduced expression of total 
OCTNs from the same period. OCT-2 expression was also reduced since week 8 in FO rats, 
indicating a decrease in dopamine uptake from circulation. These results may help to 
explain the lower values of urinary dopamine excretion induced by FO and are in 
accordance with other studies in which a high fructose diet was associated with impaired 
OCTs expression and activity and renal dysfunction [30,31].  
In our study, FO rats showed higher SBP levels respect to control since week 4 of 
treatment, reaching the highest levels at weeks 8 and 12 with values close to 160 mmHg. 
Although the precise mechanism by which hypertension develops in states of insulin 
resistance is still unknown, it has been reported both in patients with essential 
hypertension and in rats with insulin resistance by FO, a reduced urinary dopamine 
excretion together with reduced endogenous content of the amine, inversely proportional 
to the levels of blood pressure [16,32]. Supporting this evidence, a progressive increase of 
the urinary L-dopa/dopamine ratio, was found from week 4 of treatment, with a positive 
significant correlation with SBP levels since the same time period.  
Dopamine exerts its actions by binding to receptors classified into D1-like (D1 and 
D5) and D2-like (D2, D3 and D4) subtypes based on their structure and pharmacological 
properties [13,26].  In conditions of normal sodium balance, more than 50% of renal 
















significantly reduced since week 4 of treatment in FO rats. These results are consistent 
with other studies showing alterations in D1R expression and functionality in experimental 
models of insulin resistance [14,16,34].  Na+, K+-ATPase, an enzymatic pump of basolateral 
localization in renal tubular cells, is inhibited by dopamine mainly through D1R [26]. It has 
been reported that Na+, K+-ATPase is stimulated in states of insulin resistance and chronic 
exposure of kidney cells to hyperinsulinemia, leading to increased reabsorption of sodium 
and water and therefore to hydrosaline retention [34,35].  In this way, a defective D1R in a 
context of insulin resistance could lead to stimulation and increased expression of Na+, K+-
ATPase, as it was found in FO rats since week 4 in our study.  
Several clinical studies have proposed the existence of a relationship between 
metabolic syndrome and renal disease [8].  Microalbuminuria is an early indicator of 
kidney disease and a predictor of ischemic heart disease in essential hypertension [36]. On 
the other hand, nephrin is a transmembrane protein located at the specialized podocyte 
cell–cell junction that constitutes the slit diaphragm, maintaining the integrity of the 
filtration barrier of glomerulus [37]. Several studies have demonstrated the onset of renal 
damage with microalbuminuria and nephrin expression alterations in FO rats [11,38,39].  
In our study, microalbuminuria and a significant reduction in nephrin expression were 
observed at week 12 in FO rats, evidencing the existence of structural alterations in the 
filtration barrier.  
 In conclusion, this study demonstrates that insulin resistance induced by FO is 
associated with an impairment in RDS since week 4 of treatment, given by alterations in L-
















be proposed as one of the mechanisms leading to sodium retention and hypertension. FO 
is also associated to renal damage over time, evidenced by the presence of 
microalbuminuria and reduced nephrin expression at week 12 of treatment. Taking into 
consideration that alterations in the L-dopa/dopamine ratio were evidenced since week 4 
of FO, the urinary L-dopa/dopamine index could be proposed as a marker of renal 
dysfunction that temporarily precedes renal structural damage evidenced by 
microalbuminuria and reduced nephrin expression. A suggested mechanism is illustrated 
in figure 10. 
 This is the first study to propose the use of the urinary L-dopa/dopamine index 
as marker of renal dysfunction in a model of metabolic syndrome induced by FO. Further 
studies are needed to confirm the relevance of the index in other experimental models of 
hypertension and/or metabolic syndrome. This would set the precedent in the proposal of 
the use of this biochemical parameter in future clinical studies in order to assess its 
usefulness as a diagnostic marker, as predictor of response to treatment or to monitor 
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Figure Legends 
 
Figure 1: Renal excretion of L-dopa and dopamine from control and fructose overloaded 
rats at weeks 4, 8 and 12 of treatment. 
 
C: control group; FO: 10% fructose overload group; *p<0.05; #p<0.01; &p<0.001; versus respective 
control. 
 
Figure 2: Urinary L-dopa/dopamine ratio from control and fructose overloaded rats at 
weeks 4, 8 and 12 of treatment.  
 
C: control group; FO: 10% fructose overload group; &p<0.001 versus respective control 
 
Figure 3: Correlation between SBP and urinary L-dopa/dopamine ratio from control and 
fructose overloaded rats at weeks 4, 8 and 12 of treatment.  
 



















Figure 4: Renal cortex protein expression of LAT-1 (a) and LAT-2 (b) from control and 
fructose overloaded rats at weeks 4, 8 and 12 of treatment.  
 




Figure 5: Renal cortex protein expression of OCT-2 (a), OCT-N1/2/3 (b), OCT-N1 (c) and D1-
R (d) from control and fructose overloaded rats at weeks 4, 8 and 12 of treatment.  
 





Figure 6: Values of specific activity of the Na+, K+-ATPase pump in renal cortex from 
control and fructose overloaded rats at weeks 4, 8 and 12 of treatment.  
 



















Figure 7: Immunofluorescence of Na+, K+-ATPase in renal cortex from control and fructose 
overloaded rats at weeks 4, 8 and 12 of treatment.  
C: control group; FO: 10% fructose overload group; a) C 4 weeks; b) FO 4 weeks; c) C 8 weeks; d) 
FO 8 weeks; e) C 12 weeks; f) FO 12 weeks.  
 
Figure 8: Urinary albumin/creatinine ratio from control and fructose overloaded rats at 
weeks 4, 8 and 12 of treatment.  
 
C: control group; FO: 10% fructose overload group; Alb: albumin; Cr: creatinine; &p<0.001 versus 
respective control. 
 
Figure 9: Nephrin expression in renal cortex from control and fructose overloaded rats at 
weeks 4, 8 and 12 of treatment. 
 
C: control group; FO: 10% fructose overload group; AU: arbitrary units; *p<0.05 versus respective 
control. 
 
Figure 10: A proposed mechanism by which insulin resistance leads to hypertension and 
















List of non-standard abbreviations 
 
COMT: catechol-O-methyltransferase  
D1R: dopamine receptor D1 
FO: fructose-overloaded 
LAT: L-aminoacid transporter 
MAO: monoamine oxidase  
NHE3: sodium–hydrogen exchanger 3  
OCT/OCTN: organic cation transporter 
RDS: renal dopaminergic system 



















Table 1: Physiological and metabolic parameters from control and fructose overloaded 
rats at weeks 4, 8 and 12 of treatment. 
 
 4 weeks 8 weeks 12 weeks 
C FO C FO C FO 














Caloric intake (kCal/day) 85±5 96±7 80±6 92±7 99±6 110±9 
Body Weight (g) 305±23 325±30 410±23 416±16 417±34 437±14 





Colesterol (mg/dL) 50±7 61±10 43±7 37±7 63±11 83±14 





Glycemia (mg/dL) 127±6 145±7 128±4 150±14 122±4 147±19 
Insulinaemia (ng/mL) 0.22±0.02 0.38±0.06* 0.35±0.04 0.58±0.08* 0.34±0.02 0.589±0.09* 




























Table 2: Renal functional parameters from control and fructose overloaded rats at weeks 
4, 8 and 12 of treatment. 
 
 4 weeks 8 weeks 12 weeks 
C FO C FO C FO 
Diuresis (mL/day/kg) 38.69±4.66 75.45±6.30* 38.12±4.41 74.35±6.97* 35.20±3.84 70.10±6.11* 
CrCl (mL/min/kg) 4.43±0.56 4.58±0.40 4.02±0.61 4.06±0.29 3.82±0.36 3.64±0.27 
FENa (%) 0.41±0.03 0.28±0.03* 0.32±0.03 0.22±0.01* 0.35±0.04 0.2±0.02
#
 








C: control group; FO: 10% fructose overload group; ClCr: creatinine clearance; FENa: fractional 
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